Current Report Filing (8-k)
March 23 2017 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 22, 2017
PIERIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Nevada
|
|
001-37471
|
|
EIN
30-0784346
|
(State
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
255 State Street, 9th Floor
Boston, MA
United States
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code:
857-246-8998
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02 Results of Operations and Financial Condition.
The information set forth under this Item 2.02. Results of Operations and Financial Condition, including the exhibit attached
hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except
as shall be expressly set forth by specific reference in such filing.
Attached as Exhibit 99.1 is a copy of a press release of Pieris
Pharmaceuticals, Inc. (the Company), dated March 22, 2017, announcing certain financial results for the year ended December 31, 2016.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits.
99.1 Press release announcing
financial results for the year ended December 31, 2016, dated March 22, 2017.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Dated: March 22, 2017
|
|
|
|
PIERIS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Lance Thibault
|
|
|
|
|
Name:
|
|
Lance Thibault
|
|
|
|
|
Title:
|
|
Acting Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release announcing financial results for the year-ended December 31, 2016, dated March 22, 2017.
|
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From Sep 2023 to Sep 2024